Morpholines

Name
Morpholines
Accession Number
DBCAT000802
Description
Not Available
Drugs
DrugDrug Description
TimololA non-selective beta adrenergic blocker used in the treatment of elevated intraocular pressure in ocular hypertension or open angle glaucoma.
MoricizineAn antiarrhythmic used to treat arrhythmias.
PhenmetrazineUsed as an anorectic in the treatment of obesity.
DextromoramideAn opioid analgesic structurally related to methadone and used in the treatment of severe pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1070)
RivaroxabanA factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations.
ViloxazineIndicated for the treatment of clinical depression.
MolsidomineThe indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension [L1370, L1371].
LinsidomineNot Annotated
XamoterolXamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but...
ReboxetineFor the treatment of clinical depression.
AprepitantA substance P/neurokinin 1 receptor antagonist used to treat nausea and vomiting caused by chemotherapy and surgery.
EteplirsenAn antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD) only in patients who are confirmed to have a specific type of mutation.
FosaprepitantAn antiemetic drug used in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting caused by chemotherapy.
RadavirsenRadavirsen is under investigation in clinical trial NCT01375985 (Safety Study of Single Administration Intravenous Treatment for Influenza).
ViltolarsenAn antisense phosphorodiamidate morpholino oligonucleotide specific for exon 53 of the human DMD gene that is capable of inducing exon 53 skipping to produce a functional truncated dystrophin protein in Duchenne muscular dystrophy patients with specific underlying mutations.
CasimersenAn antisense phosphorodiamidate morpholino oligonucleotide used to treat Duchenne muscular dystrophy patients with mutations amenable to exon 45 skipping.
Drugs & Drug Targets
DrugTargetType
TimololBeta-1 adrenergic receptortarget
TimololBeta-2 adrenergic receptortarget
TimololCytochrome P450 2D6enzyme
TimololP-glycoprotein 1transporter
TimololCytochrome P450 2C19enzyme
TimololLysozymetarget
MoricizineSodium channel protein type 5 subunit alphatarget
PhenmetrazineSodium-dependent noradrenaline transportertarget
PhenmetrazineSodium-dependent dopamine transportertarget
RivaroxabanCoagulation factor Xtarget
RivaroxabanCytochrome P450 3A4enzyme
RivaroxabanCytochrome P450 2J2enzyme
RivaroxabanP-glycoprotein 1transporter
RivaroxabanCytochrome P450 3A5enzyme
RivaroxabanATP-binding cassette sub-family G member 2transporter
ViloxazineSodium-dependent noradrenaline transportertarget
ViloxazineCytochrome P450 1A2enzyme
MolsidomineGuanylate cyclase soluble subunit alpha-2target
MolsidomineGuanylate cyclase soluble subunit alpha-2enzyme
MolsidominecGMP-specific 3',5'-cyclic phosphodiesteraseenzyme
XamoterolBeta-1 adrenergic receptortarget
ReboxetineSodium-dependent noradrenaline transportertarget
ReboxetineCytochrome P450 3A4enzyme
ReboxetineCytochrome P450 2D6enzyme
ReboxetineP-glycoprotein 1transporter
AprepitantNeurokinin 1 receptortarget
AprepitantCytochrome P450 3A4enzyme
AprepitantCytochrome P450 2C9enzyme
AprepitantCytochrome P450 2C19enzyme
EteplirsenDMD-001 gene (exon 51 target site)target
FosaprepitantCytochrome P450 3A4enzyme
FosaprepitantCytochrome P450 2C9enzyme
ViltolarsenDMD gene (exon 53 viltolarsen target site)target
CasimersenDMD gene (exon 45 casimersen target site)target
CasimersenCytochrome P450 3A4enzyme
CasimersenCytochrome P450 3A5enzyme
CasimersenCytochrome P450 2C9enzyme
CasimersenCytochrome P450 2C19enzyme